About Our Academic Proofreading Services:
Bioscience Advising is an internationally-recognized biomedical research consultancy with a specific focus on the preparation/editing of all types of research documents. The company is based in Ypsilanti, MI. We are committed to adhering to the highest standards in editing, developing, critiquing and refining your documents for the greatest optimization of publication (in respected journals), or achieving successful research funding.
Curt Balch, PhD
Dr. Balch coordinates company business, customer service, and peer review. He is currently a Research Scholar at the Ronin Institute and The Complex Biological Systems Alliance. He was previously employed for ten years as a faculty member of the Indiana University School of Medicine, where he remains an adjunct faculty member. Curt also currently is an adjunct senior research at the University of Toledo. He received his Ph.D. in biochemistry and molecular biology from the University of Cincinnati (UC), followed by postdoctoral training in protein biochemistry, epigenetics, and cancer biology at UC and Indiana University.
In addition to five years of employment in the biotechnology industry, he has authored over 30 peer-reviewed basic and translational research publications (see curriculum vitae), and has also served as a reviewer for numerous well-respected biomedical research journals, including Clinical Cancer Research, Cancer Research, and the Journal of Urology.
Moreover, with over seven years of service on National Cancer Institute review committees, Curt is intimately familiar with the peer-review process and the required attributes of successfully funded grant applications. That experience has resulted in his receipt of three funding awards for his own independent research. Finally, in separate work in the biotechnology industry, his consultation on grant preparation has led to the successful funding of four small business research innovation (SBIR) awards.
Publications Edited by Bioscience Advising
Kim et al., 2015. Effects of low-fat diet and aging on metabolic profiles of Creb3l4 knockout mice. Nutr Diabetes5:e179. doi 10.1038.
Yeh et al., 2015. Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma. Oncotarget 2015 July 22 [Epub ahead of print].
Koh et al., 2015. Transcriptional activation of Apaf1 by KAISO (ZBTB33) and p53 is attenuated by RelA/p65. Biochim Biopys Acta 1849(9): 1170.
Zu et al., 2015. Platelet-derived growth factor-BB enhances MSC-mediated cardioprotection via suppression of miR-320 expression. Am J Physiol Heart Circ Physiol 308(9): H980.
Park et al., 2015. Network comparison of inflammation in colorectal cancer and Alzheimer’s disease. Biomed Res Intl 2015:205247. doi: 10.1155/2015/205247. Epub 2015 Jul 26.
Kim et al., 2014. ZBTB2 increases PDK4 expression by transcriptional repression of RelA/p65. Nucleic Acids Res43(3): 1609.
Koh et al., 2014. KAISO, a critical regulator of p53-mediated transcription of CDKN1A and apoptotic genes. Proc Natl Acad Sci 111(42): 15078.
Choi et al., 2014. Promyelocytic leukemia zinc finger-retinoic acid receptor alpha, an oncogenic transcriptional respressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes. J Biol Chem 289(27): 18641.
Choi et al., 2104. Role of promyelocytic leukemia zinc finger (PLZF) in cell proliferation and cyclin-ddependent inhibitor 1A (p21WAF/CDKN1A) gene repression. J Biol Chem 289(7): 18625.
Koh et al., 2014. Kaiso is a key regulator of spleen germinal center formation by repressing Bcl6 expression in splenocytes. Biochem Biophys Res Commun: 442(3-4): 177.
Chang et al., 2014. HNF4-alpha is a therapeutic target that links AMPK to WNT signaling in early-stage gastric cancer. Gut 2014;0:1–14. doi:10.1136.
Publications Written by Bioscience Advising
Nam et al., A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer. Cancer Lett 356(2 Pt B):880.
R21 Grants Written (not Merely Edited) by Bioscience Advising
Principal Investigator, Amit K. Tawari, University of Toledo. “Targeting Triple Negative Breast Cancer Using Selective Gtpase Dynamin-Related Protein-1 (Drp1) Inhibitors.” Currently under review.
Principal Investigator, Amit K. Tawari, University of Toledo. “Targeting chemoresistant colon cancer with plant-derived synthetic analogues that inhibit embryonic signaling pathways.” Currently under review.
Successfully Funded Grant Applications Edited by Bioscience Advising
5R01GM104483. A transformational bioinformatics approach for drug interaction research. Dr. Lang Li, Principle Investigator, $362,872 (FY2015)
5R01CA085289-09. DNA methylation and ovarian cancer, Kenneth Nephew, Principle Investigator, $233,593 (FY 2012)